On Monday, Novo Nordisk initiated a global phase IIIa trial of semaglutide in tablet form, as a treatment for obesity, the pharmaceutical company confirms to MedWatch.
The phase IIIa trial, called Oasis 1, comes at a time when Novo Nordisk is already experiencing huge US demand for its newly-launched obesity drug Wegovy. In its own phase III trials, this drug demonstrated an average weight loss of 17-18 percent in participants without type 2 diabetes, and the two drugs are based on the same active ingredient, semaglutide - though Wegovy is administered via injection.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.